PHPT1

PHPT1 is the principal mammalian protein histidine phosphatase, removing phosphate from phosphohistidine residues to regulate ion-channel activity and signal transduction (PMID:24523290). It dephosphorylates histidine 711 in the C-terminal tail of the TRPV5 Ca²⁺ channel, counteracting NDPK-B-driven channel activation and thereby modulating renal Ca²⁺ handling (PMID:24523290); PHPT1 engages TRPV5 directly through active-site residues Asp30 and Arg157, and in a pulmonary arterial smooth muscle context this interaction restrains proliferation and migration alongside dampened Akt and TGF-β/SMAD2/3 signaling (PMID:40877955). Its substrate range extends to phospholysine, as it dephosphorylates chemically phospholysinated histone H1 and polylysine in vitro (PMID:25574816). Beyond TRPV5, PHPT1 transduces TGF-β1 signals through the PI3Kγ/AKT/Rac1 axis to drive hepatic stellate cell migration and lamellipodia formation (PMID:29098317), and its abundance gates brown adipocyte differentiation, where PHPT1 is downregulated early in differentiation and acts as a brake on adipogenesis (PMID:31752058). PHPT1 protein levels are controlled post-translationally: the E3 ubiquitin ligase FBXO32 targets PHPT1 for ubiquitination and degradation, and loss of FBXO32 stabilizes PHPT1, activates ERK/MAPK signaling, and promotes lung cancer proliferation (PMID:35411430). Its catalytic activity is tractable to small-molecule inhibition, with covalent (norstictic acid), non-competitive (illudalic acid analogs), and cysteine-dependent (phenylarsonic acid) inhibitors characterized in vitro (PMID:35859860, PMID:37267298, PMID:41706466).

1. 2014 High

   Establishing a direct physiological substrate answered whether PHPT1 acts on phosphohistidine in a specific channel and to what end, placing it as a negative regulator of TRPV5-mediated Ca²⁺ transport.

   Evidence Inside-out patch clamp with shRNA knockdown and NDPK-B knockout mice measuring urinary Ca²⁺

   PMID:24523290

   Open questions at the time

   • Does not resolve PHPT1 subcellular localization at the channel
   • Stoichiometry and kinetics of H711 dephosphorylation not quantified
2. 2014 Medium

   Identification of a proteasome-degraded splice variant raised the question of how PHPT1 protein levels are set, hinting at post-translational control of the active enzyme pool.

   Evidence Ectopic expression of transcript variant 6 in HeLa cells with proteasome inhibitor rescue and in silico modeling

   PMID:25450458

   Open questions at the time

   • Endogenous expression and function of the variant unknown
   • E3 ligase responsible not identified in this study
3. 2015 Medium

   Testing whether PHPT1 acts beyond phosphohistidine showed it can also remove phosphate from phospholysine, broadening its biochemical substrate class while excluding free phosphoarginine.

   Evidence In vitro dephosphorylation of chemically phospholysinated histone H1 and polylysine with malachite green and MS confirmation

   PMID:25574816

   Open questions at the time

   • No physiological phospholysine substrate identified
   • Catalytic mechanism on phospholysine vs phosphohistidine not compared
4. 2016 Medium

   Probing redox sensitivity addressed whether oxidative stress regulates PHPT1, finding Met95 in the substrate-binding region is selectively oxidized but without negative impact on activity.

   Evidence LC-MS/MS site-specific oxidation mapping, molecular dynamics, and MS-based activity assay after H₂O₂ treatment

   PMID:27034094

   Open questions at the time

   • Functional consequence of Met95 oxidation in cells unresolved
   • Whether other residues mediate redox regulation not addressed
5. 2017 Medium

   Linking PHPT1 to TGF-β1 signaling answered whether it participates in motility pathways, placing it upstream of PI3Kγ/AKT/Rac1 to drive hepatic stellate cell migration.

   Evidence Transwell and 3D collagen migration assays with knockdown/overexpression and pathway western blotting

   PMID:29098317

   Open questions at the time

   • Direct phosphohistidine substrate in this pathway not identified
   • Mechanistic link between phosphatase activity and PI3Kγ activation unresolved
6. 2020 Medium

   Reciprocal manipulation in brown adipocyte precursors established that PHPT1 abundance gates differentiation, connecting histidine phosphorylation status to adipogenic fate.

   Evidence Knockdown and overexpression in brown adipocyte precursors with differentiation assays and western blotting

   PMID:31752058

   Open questions at the time

   • Relevant phosphohistidine substrate in adipogenesis unknown
   • Transcriptional program downstream of PHPT1 not mapped
7. 2022 Medium

   Identifying FBXO32 as the E3 ligase resolved how PHPT1 protein levels are controlled and tied that control to ERK/MAPK-driven cancer proliferation.

   Evidence Mass spectrometry, ubiquitination assays, FBXO32 knockdown with ERK/MAPK readout, and in vitro/in vivo lung tumor growth

   PMID:35411430

   Open questions at the time

   • Ubiquitination site on PHPT1 not mapped
   • Whether degradation is regulated by upstream signals unknown
8. 2022 Medium

   Characterizing norstictic acid demonstrated PHPT1 is a druggable enzyme, providing the first kinetically defined covalent inhibitor.

   Evidence Fluorogenic inhibitor screen of ~4000 compounds with IC50/KI/kinact kinetics and phosphatase selectivity counterscreen

   PMID:35859860

   Open questions at the time

   • Covalent adduct site on PHPT1 not defined
   • Cellular target engagement not demonstrated
9. 2023 Medium

   Illudalic acid analogs defined a non-covalent, non-competitive inhibition mode independent of cysteine residues, distinguishing distinct inhibitor chemotypes for PHPT1.

   Evidence In vitro enzymatic inhibition with kinetic analysis and cysteine-to-alanine mutagenesis

   PMID:37267298

   Open questions at the time

   • Binding site of the analogs not structurally resolved
   • Cellular activity not tested
10. 2025 Medium

    Mapping a direct PHPT1–TRPV5 interaction via active-site residues and testing it in a disease model established PHPT1 as a protective regulator in hypoxic pulmonary hypertension.

    Evidence Co-IP with D30A/R157A active-site mutagenesis plus PHPT1 knockout/overexpression rat HAPH model with hemodynamics, RNA-seq, and western blotting

    PMID:40877955

    Open questions at the time

    • Causal phosphohistidine substrate driving TGF-β/SMAD changes not pinned down
    • Single lab; reciprocal validation in human tissue lacking
11. 2026 Medium

    Phenylarsonic acids revealed a cysteine-dependent inhibition route, showing solvent-exposed cysteines can be exploited for PHPT1 inhibition after reduction to thiophilic As(III).

    Evidence In vitro enzymatic inhibition with kinetic mode analysis, cysteine-to-alanine mutagenesis, and DTT reduction experiments

    PMID:41706466

    Open questions at the time

    • Selectivity over other cysteine-containing phosphatases not established
    • No cellular or in vivo validation

• It remains unknown which physiological phosphohistidine substrates underlie PHPT1's roles in TGF-β signaling, adipogenesis, and cancer, and whether a unified structural mechanism connects its catalytic action across these contexts.
• No high-resolution structure of PHPT1 bound to a physiological substrate
• Substrate repertoire beyond TRPV5 and in vitro phospholysine targets uncharacterized
• Tissue-specific regulation of PHPT1 abundance and activity incompletely defined